Clinical trials: Atopic
Atopic Dermatitis, Psoriasis
Meditation in Inflammatory Dermatosis
Psoriasis and atopic dermatitis are multifactorial inflammatory dermatoses, with a very high prevalence, reaching more than 120 million patients in the world.
- Conditions
- Atopic Dermatitis, Psoriasis, Pruritus
- Trial name
- MediDermIn (NCT05500794)
- Testing
- MBSR (Mindfulness-Based Stress Reduction)
- Where
- France
- Volunteers
- 72 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Dermatitis, Atopic
Study to Evaluate the Response to Treatment and Safety of 0.03% Tacrolimus (FK506) Ointment Administered in Pediatric Patients With Moderate to Severe Atopic Dermatitis
Objective of this study is to further assess the response to treatment and safety of 0.03% tacrolimus (FK506) ointment when used for 6 months in pediatric patients with moderate to severe atopic dermatitis, known to be responsive…
- Trial name
- NCT00691262
- Testing
- tacrolimus ointment
- Where
- 9 sites in Italy
- Volunteers
- 166 people
- Sponsor
- Astellas Pharma Inc
Atopic Dermatitis
Twice Daily Versus Twice Weekly Soak-and-Seal Baths in Pediatric Atopic Dermatitis
There are few studies evaluating best bathing practices in the management of pediatric atopic dermatitis (AD). Trans-epidermal water loss plays a key role in the pathophysiology of AD.
- Trial name
- NCT03397979
- Testing
- Infrequent versus Frequent Soaking Baths
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- MaineHealth
Atopic Dermatitis
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children and adolescents (6 to <18 Years Old) with moderate atopic dermatitis.
- Trial name
- TRuE-AD5 (NCT06832618)
- Testing
- Ruxolitinib, Vehicle Cream
- Where
- 93 sites in United States, Belgium and 8 more
- Volunteers
- 159 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
Observational Study to Evaluate the Actual Use of Elidel® in Chinese Patients With Mild to Moderate Atopic Dermatitis
The primary objective of the present multicentre, prospective, non-interventional study (NIS) is gathering knowledge on the actual use and effectiveness of Elidel® in Chinese patients with mild to moderate AD affecting sensitive…
- Trial name
- NCT04976868
- Testing
- Pimecrolimus 1% Top Cream
- Where
- 10 sites in China
- Volunteers
- 130 people
- Sponsor
- Mylan Inc.
Atopic Dermatitis/Eczema
Atopic Dermatitis Adherence Study
Forgetting is usually listed as the most important cause of low adherence among patients. Most studies to date have looked at the adherence of adults or adolescent population.
- Trial name
- NCT02169986
- Testing
- electronic reminders
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of British Columbia
Atopic Dermatitis
Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis
The purpose of this study is to assess the pharmacokinetic parameters and safety of topical MM36 (OPA-15406) ointment in pediatric subjects with atopic dermatitis under maximal use conditions.
- Trial name
- NCT02945657
- Testing
- MM36 topical ointment, 1%
- Where
- 12 sites in United States, Honduras and 1 more
- Volunteers
- 32 people
- Sponsor
- Medimetriks Pharmaceuticals, Inc
Atopic Dermatitis
Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis
The purpose of this study is to assess the efficacy of short-term treatment with fluocinonide cream 0.1% (Vanos®) in the treatment of atopic dermatitis (AD).
- Trial name
- NCT01469767
- Testing
- Fluocinonide cream
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Wake Forest University
Atopic Dermatitis (AD)
A Study to Assess Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Chinese Participants Receiving Upadacitinib for Atopic Dermatitis (AD) Through Chart Review
Atopic Dermatitis (AD) is a common, chronic, and flaring systemic inflammatory skin disorder characterized by intensely pruritic and distressing skin eruptions.
- Trial name
- NCT06503536
- Where
- China
- Volunteers
- 150 people
- Sponsor
- AbbVie
Alopecia Areata, Alopecia Totalis
The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
The study series consists of three studies with the aim to assess the incidence, prevalence, risk factors, comorbidities and management of patients with alopecia areata in Czech Republic based on the patients and registry of a…
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis, Alopecia Areata (& Ophiasis)
- Trial name
- NCT05098600
- Testing
- Exposure of interest
- Where
- Czechia
- Volunteers
- 123 people
- Sponsor
- Faculty Hospital Kralovske Vinohrady
Atopic Dermatitis
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled, parallel-group study which is 52 weeks in duration. The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of…
- Trial name
- ADvocate2 (NCT04178967)
- Testing
- Lebrikizumab
- Where
- 89 sites in United States, Bulgaria and 6 more
- Volunteers
- 445 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis, Eczema
Skin Tracker: A Mobile Health App to Monitor Skin Disease Activity and Treatment Use
Design and beta-test a research-oriented mobile health app to assess disease activity, quality of life, treatment patterns, adverse medication effects, and lifestyle factors in patients with atopic dermatitis.
- Trial name
- NCT04404075
- Testing
- SkinTracker Mobile App
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of California, San Francisco
Childhood Atopic Dermatitis
Accessible and Affordable Moisturizers for Atopic Eczema
Aqueous (EUA) cream, cetomacrogol (CMG) and emulsifying ointment (HEB) are in South Africa's essential drug list (EDL) but are not available to most rural patients.
- Trial name
- NCT02084472
- Testing
- Baby oil, petroleum jelly, Glycerine:petroleum jelly 2:1
- Where
- South Africa
- Volunteers
- 120 people
- Sponsor
- Red Cross War Memorial Childrens Hospital
Dermatitis Atopic
A Study to Assess the Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quantification in a Subset of Participants From PEDISTAD Study (OBS15333; NCT03687359)
Primary objective: To explore and quantify the association between nighttime scratching and sleep patterns objectively in pediatric participants with moderate to severe atopic dermatitis (AD) using an innovative Emerald touchless…
- Trial name
- NCT05235724
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Sanofi
Atopic Dermatitis, Eczema, Atopic
Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis
The goal of this clinical trial is to compare a step-down strategy of spacing dupilumab injections with a standard maintenance treatment in adolescents and adults with controlled Atopic dermatitis (AD) for at least six months.
- Trial name
- MADULO (NCT05642208)
- Testing
- Dupilumab step-down
- Where
- 32 sites in France, Reunion
- Volunteers
- 256 people
- Sponsor
- Nantes University Hospital
Eczema, Dermatitis, Atopic
Integrative Body-Mind-Spirit Intervention for Families With Children Suffering From Eczema
This randomized controlled trial aims to examine the efficacy of two integrative body-mind-spirit interventions, compared to a health education active control, in promoting adaptive emotional regulation and quality of life of…
- Trial name
- NCT04617977
- Testing
- I-BMS for families with children suffering from eczema, Health education for parents whose children have eczema
- Where
- Hong Kong
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Dermatitis, Atopic
Efficacy, Safety and Dose Finding Trial of Topical Jaungo Application in Atopic Dermatitis Patients
Atopic Dermatitis is a chronic relapsing eczematous skin disease with increasing prevalence. Complementary and alternative medical approaches have been employed to relieve symptoms of Atopic Dermatitis.
- Trial name
- NCT02900131
- Testing
- Jaungo
- Where
- South Korea
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Kyung Hee University Hospital at Gangdong
Down Syndrome, Alopecia Areata
Tofacitinib for Immune Skin Conditions in Down Syndrome
People with Down syndrome (DS) display widespread immune dysregulation, including several immune skin conditions. This study hypothesizes that pharmacological inhibition of the increased interferon (IFN) signaling seen in DS is…
- Conditions
- Down Syndrome, Alopecia Areata, Atopic Dermatitis / Eczema, Hidradenitis Suppurativa
- Trial name
- NCT04246372
- Testing
- Tofacitinib
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Colorado, Denver
Mild to Moderate Atopic Dermatitis
Eucrisa for Atopic Dermatitis
Patients with mild to moderate atopic dermatitis will be asked to participate in helping the study team determine how well the medication works for atopic dermatitis.
- Trial name
- NCT03250663
- Testing
- Online Treatment response, EUCRISA
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Wake Forest University Health Sciences
Atopic Dermatitis Eczema
8-Week Atopic Dermatitis (AD) Treatment Study
This is a study to investigate the clinical effectiveness of the Sponsor's experimental cream treatment on eczema as measured by visual grading of SCORAD (scoring of atopic dermatitis).
- Trial name
- NCT03386032
- Testing
- Investigational OTC Cream, 0.05% Desonide
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Procter and Gamble